# Multispan, Inc.

> Multispan, Inc. is a Hayward, California biotech that builds the cell lines and assays drug hunters use to interrogate G protein-coupled receptors (GPCRs), the largest druggable target family in the human genome. Founded in 2004 by Helena Mancebo, the company has assembled one of the industry's largest libraries of clonally derived, GPCR-expressing stable cell lines - 600+ lines and 2,000+ ready-to-use reagents - and pairs them with custom assay development, compound profiling, antibody work, and CRISPR cell engineering. Its MULTISCREEN platform and proprietary HEx high-expression cell technology let pharmaceutical and academic teams screen, profile, and validate candidate drugs against receptors that are notoriously hard to express and measure.

- **Founded:** 2004
- **Headquarters:** Hayward, California, United States
- **Founders:** Helena Mancebo (Founder & CEO)
- **Team size:** ~11 employees
- **Products:** MULTISCREEN stable cell lines, HEx High-Expression cell technology, Assay kits & reagents, Custom cell line development, Compound profiling & screening
- **Notable:** Built one of the industry's largest libraries of human GPCR clones and GPCR-expressing stable cell lines (600+ lines, 2,000+ reagents)., Developed proprietary HEx High-Expression cell technology enabling difficult-to-express receptors., Signed a 2006 licensing deal with Medarex to support therapeutic antibody discovery.

## Products & services

- **MULTISCREEN stable cell lines** — A portfolio of 600+ clonally derived, HTS-ready stable cell lines expressing human GPCRs and other targets.
- **HEx High-Expression cell technology** — Proprietary high-expression cell lines used both for sensitive assays and as whole-cell immunogens for antibody generation.
- **Assay kits & reagents** — 2,000+ ready-to-use tools including GPCR calcium and cAMP assay kits, cell proliferation kits, and membrane preparations.
- **Custom cell line development** — Bespoke HTS-ready and CRISPR-engineered cell lines built to a client's target and assay needs.
- **Compound profiling & screening** — Receptor profiling across up to 250 druggable GPCRs and 75 orphans, including biased-signaling and internalization assays.
- **GPCR antibody profiling & generation** — Antibody characterization and generation support leveraging high-expression cell lines.
- **Beta-Arrestin Sensor Technology** — MULTISCREEN beta-arrestin sensor assays for measuring receptor recruitment and signaling bias.

## Achievements

- Built one of the industry's largest libraries of human GPCR clones and GPCR-expressing stable cell lines (600+ lines, 2,000+ reagents).
- Developed proprietary HEx High-Expression cell technology enabling difficult-to-express receptors.
- Signed a 2006 licensing deal with Medarex to support therapeutic antibody discovery.
- Maintained a reputation as a go-to GPCR specialist with strong repeat business over 20+ years.

## Latest updates

- **2023-01** — Refreshed company branding and logo (multispan-logo-2023).
- **2007-10** — Raised $600K Series B funding.
- **2006-01** — Announced licensing agreement with Medarex for HEx GPCR cell lines used in antibody development.

## Links

- Website: https://multispaninc.com
- LinkedIn: https://www.linkedin.com/company/multispan-inc
- Twitter/X: https://twitter.com/MultispanGPCR
- YouTube: https://www.youtube.com/results?search_query=multispan+gpcr
- Facebook: https://www.facebook.com/multispangpcr

---

Profile page: https://yespress.io/multispan-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-13